chief science officer

E-mail: jxiang@newlegacy.com

Dr. Xiang is the Chief Scientific Officer of New Legacy Group, as well as the Chief Investment Officer and Co-Founder of Syno Capital, an affiliated global healthcare and biotech investment firm that emphasizes on cross-border collaborations between United States and China. In addition, Dr. Xiang is a senior advisor to Zhong An Insurance, a pioneer online insurance platform in China jointly led by Alibaba, Tencent and Ping An Insurance. He advises the firm on healthcare-related products and manages executive-level investor relations. Dr. Xiang also serves as Board Director with Cynvenio Biosystems, a liquid biopsy diagnostics firm in Los Angeles, CA and Orig3n, a stem cell (iPSC) technology company in Boston, MA.

Prior to his current roles, Dr. Xiang served as a Senior Scientist at Schrodinger Inc., a software and consulting firm backed by industry leaders including David E. Shaw and Bill Gates that specializes in computer-aided drug design for biopharma companies. He was responsible for developing next- generation computational tools for rational drug design and various other client drug development programs. Previously, Dr. Xiang was also part of Genentech’s Medicinal Chemistry team, where he participated in numerous lead drug candidate optimization projects.

Dr. Xiang holds a doctoral degree in Molecular Biophysics from Washington University Medical School. His research focus was the development of cutting-edge computational models to optimize the drug design process. Dr. Xiang authored several publications on this topic in internationally recognized peer-reviewed journals, including Journal of Computational Chemistry and Journal of Chemical Theory and Computation. He graduated Magna Cum Laude from Washington University in St. Louis with bachelor’s degrees in Biomedical Engineering, Economics, Mathematics and Computer Science.